

Conference Call Invitation

Ladies and Gentlemen,

Phase III Trial Results for Rivaroxaban will be presented at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia, from December 8 to 11, 2007. On this occasion we cordially invite you to a conference call for investors and analysts.

Live Now !	Full details on the webcast and additional background information available at
	www.investor.bayer.com / www.investor.bayer.de
Tuesday December 11, 2007	Investor Conference Call to review Rivaroxaban data presented at ASH with Dr. Kemal Malik, Head of Global Development at Bayer Schering Pharma, Dr. Frank Misselwitz, Head Therapeutic Area Cardiovascular, Global Clinical Development, and Dr. Alexander Rosar, Head of Investor Relations
2:00 p.m. CET	<u>Dial-in Numbers</u> International: +44 207 153 2027 UK: 0207 153 2027 US: +1 888 457 4228 Germany: 06103 485 3000 If you are unable to participate in the conference, a recording will be available for access by touch tone telephone until December 14, 2007. <u>Replay Dial-in Numbers</u> International: +44 207 190 5901, Passcode: 137635# UK: 0207 190 5901, Passcode: 137635# US: +1 303 590 3030, Passcode: 3809556# Germany: 069 58999 0567, Passcode: 137635# Live audio broadcast (English only) available on the Internet.
7:00 p.m. CET	On-demand version of the conference call webcast available on the Internet.

CET = Central European Time = GMT + 1 hour

Best regards,
Bayer Investor Relations